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Editorial on the Research Topic
Hybrids Part B: Hybrids for Drug Delivery
Hybrids, consisting of two or more components at the nanometer or molecular level, have
recently emerged as novel biomaterials for drug delivery applications. Hybrids usually show
characteristics in between the original components, but also may exhibit new and unique
physical, chemical, and/or biological properties not possessed by the original components. Hybrid
systems could combine the benefits of different structural components to synergize the outcome
of drug delivery for therapeutic applications. Many attempts have been dedicated to design
and synthesize novel hybrid biomaterials with several concurrent features, such as favorable
size/shape for efficient drug loading and controlled drug release, desired surface properties for
targeting specific organs/tissues/cells, and satisfactory biocompatibility and biodegradation rate for
clinical translation.
This Research Topic invited researchers to contribute studies on recent advances in hybrids
for drug delivery. We have collected three review articles and one original research article, which
highlight several emerging trends of hybrids for drug delivery.
Xu et al. in their publication present a synthesis, in vitro release study, cytotoxicity analysis, and
in vivo immune response examination of fabricated organic–inorganic hybrid nanoparticles used as
the carriers of zoledronic acid. Those nanorods are intended to be used for osteosarcoma therapy.
They consist of hyaluronic acid/polyethylene glycol polymer shell and a nano-hydroxyapatite core
with zolendronic acid on it. The authors demonstrated that the compact and stable structure could
achieve high drug loading efficiency, sustained drug release, and favorable biocompatibility. In vitro
and in vivo experiments revealed the low cytotoxicity and acceptable immune response under
low-dose nanoparticle treatment.
Cai et al. review the recent progress in the synthesis and biomedical applications of hybrid
hydrogels. Particularly, novel approaches for fabricating micro/nano structure on hydrogels,
including click reaction implementation, 3D printing and photopatterning, are introduced. In
this review article, the authors also demonstrate the great potential of hybrid hydrogels in cancer
therapeutic delivery, drug discovery, and regenerative medicine.
Yao et al. give an overview about the application and development of hybrid nanoparticles as
drug carriers, and discuss the roles of nanoparticles and hybrid nanoparticles for drug delivery
in chemotherapy, targeted therapy, and immunotherapy and describe the targeting mechanism of
nanoparticle-based drug delivery as well as its function on reversing drug resistance.
Huang et al. summarize the recent advances of hybrids or nanomaterials designed for targeted
therapy of kidney diseases and discuss the great potential of hybrids or nanomaterials for the
delivery of immunosuppressants like tacrolimus and triptolide, antioxidants, or siRNAs. In this
review article, the authors also highlight the achieved superior therapeutic effects and reduced
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systemic side effects by hybrids or nanomaterials in kidney
disease animal models.
In summary, this Research Topic covers recent advances in
the hybrids for drug delivery, providing new aspects of the roles
of hybrids in delivering drugs for enhancing the therapeutic
effects and reducing the side effects. The editors hope that the
Research Topic “Hybrids Part B: Hybrids for Drug Delivery”
will contribute to the progress of research and development
activities in the field of hybrids for drug delivery, inspiring future
work leading to the expansion of the biomedical applications
of hybrids.
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